Stoke Therapeutics (NASDAQ: STOK)
Stoke Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Stoke Therapeutics Company Info
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
News & Analysis
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
This small-cap biotech might be a hidden gem.
Why Shares of Stoke Therapeutics Plummeted Tuesday
The company's shares fell after it released early trial results on its lead therapy.
Why Shares of Stoke Therapeutics Plummeted in September
After top performance in August, the biotech was hit hard.
Are Biotech IPOs A Good Investment?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.